These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22609886)

  • 41. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
    Kumar S; Wolf RC; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2002 Aug; 30(3):161-5. PubMed ID: 12189534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
    Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
    Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Folic acid supplementation during methotrexate immunosuppression is not associated with early toxicity, risk of acute graft-versus-host disease or relapse following hematopoietic transplantation.
    Robien K; Schubert MM; Yasui Y; Martin P; Storb R; Potter JD; Ulrich CM
    Bone Marrow Transplant; 2006 Apr; 37(7):687-92. PubMed ID: 16501595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
    Malard F; Szydlo RM; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Mohty M
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
    Snyder DS; Palmer J; Gaal K; Stein AS; Pullarkat V; Sahebi F; Vora N; Nakamura R; Forman SJ
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Folinic acid administration following MTX as prophylaxis for GVHD.
    Gratwohl A
    Bone Marrow Transplant; 2009 Aug; 44(4):257. PubMed ID: 19204714
    [No Abstract]   [Full Text] [Related]  

  • 48. Minimum-Dose, Short-Term Methotrexate With Tacrolimus for Graft-vs-Host Disease Prophylaxis Following Unrelated Cord Blood Transplantation in Adults: A Retrospective Analysis at a Single Institution.
    Iino M; Sato T; Sakamoto Y
    Transplant Proc; 2021; 53(1):396-404. PubMed ID: 33308840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial.
    Bloom AI; Shapira MY; Or R; Sasson T; Resnick IB; Zilberman I; Verstandig A; Aker M; Slavin S; Muszkat M
    Clin Ther; 2004 Mar; 26(3):407-14. PubMed ID: 15110133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis.
    Yagasaki H; Kojima S; Yabe H; Kato K; Kigasawa H; Sakamaki H; Tsuchida M; Kato S; Kawase T; Muramatsu H; Morishima Y; Kodera Y
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1603-8. PubMed ID: 19896085
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Substitution of methotrexate with corticosteroid for acute graft-versus-host disease prevention in transplanted patients who develop methotrexate toxicity.
    Kim SY; Kim AR; Yoon SY; Cho YH; Lee MH
    Ann Hematol; 2016 Feb; 95(3):483-91. PubMed ID: 26658911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia.
    Onishi Y; Mori T; Yamazaki H; Takenaka K; Yamaguchi H; Shingai N; Ozawa Y; Iida H; Ota S; Uchida N; Miyamoto T; Katayama Y; Kato J; Yoshioka S; Onizuka M; Ichinohe T; Atsuta Y;
    Ann Hematol; 2021 Jan; 100(1):217-228. PubMed ID: 33033911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation.
    Nevill TJ; Tirgan MH; Deeg HJ; Klingemann HG; Reece DE; Shepherd JD; Barnett MJ; Phillips GL
    Bone Marrow Transplant; 1992 May; 9(5):349-54. PubMed ID: 1617319
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
    Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN
    Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation.
    Umeda K; Adachi S; Tanaka S; Ogawa A; Hatakeyama N; Kudo K; Sakata N; Igarashi S; Ohshima K; Hyakuna N; Chin M; Goto H; Takahashi Y; Azuma E; Koh K; Sawada A; Kato K; Inoue M; Atsuta Y; Takami A; Murata M;
    Pediatr Blood Cancer; 2015 Feb; 62(2):291-298. PubMed ID: 25307105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enteric-coated mycophenolate sodium containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT.
    Weber T; Niestadtkötter J; Wienke A; Müller-Tidow C; Müller LP
    Eur J Haematol; 2016 Sep; 97(3):232-8. PubMed ID: 26613546
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
    Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K
    Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation.
    Kwon M; Bailén R; Pascual-Cascón MJ; Gallardo-Morillo AI; García Sola A; Balsalobre P; Solán L; Dorado N; Muñoz C; Serrano D; Martínez-Laperche C; Buño I; Anguita J; Díez-Martin JL
    Blood Adv; 2019 Nov; 3(21):3351-3359. PubMed ID: 31698447
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children.
    Medina D; Estacio M; Rosales M; Manzi E
    Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):208-213. PubMed ID: 32224144
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants.
    Olsson R; Remberger M; Hassan Z; Omazic B; Mattsson J; Ringdén O
    Eur J Haematol; 2010 Apr; 84(4):323-31. PubMed ID: 20002156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.